YOLFTbeta
Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. Common Stock

AARD · NASDAQ · Healthcare / Biotechnology

1.33USD-0.19 (-12.50%)

Price History

Full chart

Market Stats

Previous Close1.52
Open1.58
Day Range1.31 – 1.70
52-Week Range3.35 – 17.94
Volume402.37K
Market Cap110.74M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.22
Dividend Yield0.00%
50-Day Avg6.20
200-Day Avg7.64

About

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Tien-Li Lee M.D.
  • Employees28
  • Headquarters4370 La Jolla Village Drive, San Diego, CA, United States, 92122, USA
  • Websitehttps://aardvarktherapeutics.com

Leadership

  • Dr. Tien-Li Lee M.D.CEO, Secretary & Chairman · b. 1975
  • Mr. Nelson B. Sun M.B.A.CFO & COO · b. 1977
  • Dr. Manasi Sinha Jaiman M.D., M.P.H.Chief Medical Officer · b. 1981
  • Dr. Dvorit Samid Ph.D.Executive Vice President of Medical Affairs
  • Dr. Zhenhuan Zheng Ph.D.Chief Research Officer
  • Mr. Ron Lewis II, Ph.D.VP & Head of CMC
  • Mr. Justin T. Stege Ph.D.VP and Head of Project Management & Strategy
  • Mr. Derrick C. LiChief Business Officer
  • Dr. Bryan Jones Ph.D.Chief Executive Officer of Ardia · b. 1964

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue0000
Cost of Revenue110.00K97.00K16.00K36.00K
Gross Profit-110.00K-97.00K-16.00K-36.00K
Operating Expense11.25M7.32M22.77M62.69M
Operating Income-11.36M-7.42M-22.79M-62.73M
EBITDA-10.76M-6.56M-22.65M-57.55M
Net Income-13.56M-7.21M-20.59M-57.59M
R&D7.17M4.48M17.36M48.94M

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets16.76M10.54M77.51M117.18M
Total Liabilities44.68M45.34M132.15M10.55M
Total Equity-27.92M-34.80M-54.64M106.63M
Cash15.56M9.73M61.64M47.05M
Total Debt262.00K162.00K779.00K441.00K
Net Debt-15.30M-9.57M-60.86M-46.61M

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.54M-5.82M-18.09M-54.17M
Investing Cash Flow-1.00M--12.00M-49.67M
Financing Cash Flow225.00K081.99M89.25M
Capital Expenditure00109.00K95.00K
Free Cash Flow-10.54M-5.82M-18.20M-54.27M
FCF to OCF100.00%100.00%100.60%100.18%

Earnings

Report DateMar 31, 2025May 14, 2025Aug 13, 2025Nov 13, 2025Mar 23, 2026Apr 6, 2026Aug 11, 2026Nov 12, 2026
EPS Estimate-0.20-0.61-0.60-0.82-0.83-0.80-0.87-0.74
EPS Actual-0.43-0.71-0.66-0.75-0.81-0.99-0.66-
Surprise-117.50%-16.39%-10.00%8.54%2.41%-23.75%24.14%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap110.74M
Enterprise Value48.49M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.63
EPS-3.22
Book Value3.42
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-73.91M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-66.02%
Return on Assets-40.38%
Shares Outstanding21.88M
Shares Float11.01M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 11.11
  • Strong Buy
    2
  • Buy
    2

Ownership Breakdown

Institutions
52.58%
Insiders
15.77%
Retail / Other
31.65%

Top Institutional Holders

  • Decheng Capital LLC
    3.92M17.90%
  • Citadel Advisors Llc
    1.28M5.86%
  • LAURION CAPITAL MANAGEMENT LP
    1.03M4.73%
  • BlackRock Inc
    792.57K3.62%
  • Vanguard Capital Management, LLC
    554.10K2.53%
  • EcoR1 Capital, LLC
    396.19K1.81%
  • Geode Capital Management, LLC
    309.45K1.41%
  • Adage Capital Partners Gp LLC
    300.00K1.37%
  • State Street Corp
    199.32K0.91%
  • UBS Group AG
    157.89K0.72%
  • AQR Capital Management LLC
    134.50K0.61%
  • Two Sigma Investments LLC
    108.38K0.50%
  • Northern Trust Corp
    88.60K0.40%
  • Vanguard Fiduciary Trust Co
    83.21K0.38%
  • Vanguard Portfolio Management, LLC
    75.15K0.34%
  • Woodline Partners LP
    72.43K0.33%
  • Renaissance Technologies Corp
    70.79K0.32%
  • Millennium Management LLC
    69.95K0.32%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    408.67K1.87%
  • iShares Biotechnology ETF
    94.15K0.43%